AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) CEO Thomas K. Equels will appear in a live, moderated "fireside" chat on the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. The discussion will focus on AIM's clinical and regulatory strategy for lead drug Ampligen, including the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer.

Equels will also review a completed Phase 2 trial with Merck evaluating Ampligen plus Keytruda (pembrolizumab) in advanced recurrent ovarian cancer; an abstract was presented at the 40th Annual SITC Meeting. Interested parties can submit questions in advance to aim@jtcir.com. A live webcast will stream on the company's Events page and a replay will be available two hours after the live presentation for 90 days.

News Market Reaction

+1.97%

5 alerts

+1.97% News Effect

-13.9% Trough in 30 hr 5 min

+$88K Valuation Impact

$5M Market Cap

0.5x Rel. Volume

On the day this news was published, AIM gained 1.97%, reflecting a mild positive market reaction. Argus tracked a trough of -13.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $88K to the company's valuation, bringing the market cap to $5M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Event date and time: December 4, 2025 at 4:00 PM ET Phase 2 trial: Phase 2 DURIPANC trial phase: Phase 1b/2 +3 more

6 metrics

Event date and time December 4, 2025 at 4:00 PM ET Scheduled time for the Virtual Investor Closing Bell fireside chat

Phase 2 trial Phase 2 Completed ovarian cancer trial of Ampligen plus Keytruda

DURIPANC trial phase Phase 1b/2 Ongoing DURIPANC trial combining Ampligen with Imfinzi

SITC meeting number 40th Annual SITC Meeting where the ovarian trial abstract was presented

Replay availability delay 2 hours Time after live webcast when replay becomes available

Replay access period 90 days Duration the webcast replay will remain accessible

Market Reality Check

Price: $1.34 Vol: Volume 26,298 is at 0.45x...

low vol

$1.34 Last Close

Volume Volume 26,298 is at 0.45x the 20-day average (58,636). low

Technical Shares trade below the $2.41 200-day MA at a pre-news price of $1.45, far under the $20.35 52-week high.

Peers on Argus

Biotech peers showed mixed moves, with names like TNFA at -9.72% and BCLI at +4....

Biotech peers showed mixed moves, with names like TNFA at -9.72% and BCLI at +4.46%, suggesting stock-specific rather than broad sector momentum around this investor event.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	CEO video update	Positive	-2.7%	CEO Corner segment on pancreatic cancer unmet need and Ampligen program.
Dec 01	Investor event notice	Positive	+2.0%	Announcement of fireside chat on Ampligen strategy and DURIPANC trial.
Nov 18	Earnings and pipeline	Neutral	-7.6%	Q3 2025 results with limited cash and continued Ampligen pipeline focus.
Nov 10	Clinical data update	Positive	-6.4%	Detailed Phase 2 ovarian data showing 50% ORR with Ampligen combo.
Nov 04	Conference abstract	Positive	-20.4%	Late-breaking SITC abstract acceptance for Ampligen ovarian cancer study.

Pattern Detected

Recent history shows frequent sell-offs after clinically positive or visibility-enhancing news, with several declines following favorable Ampligen updates and conference-related announcements.

Recent Company History

This announcement continues AIM’s recent focus on visibility and Ampligen’s oncology program. In November 2025, the company highlighted DURIPANC trial progress and ovarian cancer data, including a 50% ORR in a Phase 2 study. Third-quarter 2025 results showed limited cash of $2.4M and a net loss of $(3.3M), underscoring financing needs. A prior, nearly identical fireside-chat announcement on Dec 1, 2025 saw a modest +1.97% move, while other positive clinical headlines often coincided with price declines.

Regulatory & Risk Context

Active S-3 Shelf · $100 million

Shelf Active

Active S-3 Shelf Registration 2025-06-27

$100 million registered capacity

An effective Form S-3/A shelf filed on Jun 27, 2025 authorizes up to $100 million of various securities, giving AIM flexibility to raise capital in tranches. This supports funding needs but also introduces ongoing dilution risk when equity or equity-linked securities are issued under the shelf.

Market Pulse Summary

This announcement centered on an investor fireside chat where management planned to discuss Ampligen...

Analysis

This announcement centered on an investor fireside chat where management planned to discuss Ampligen’s clinical and regulatory strategy, including the DURIPANC trial and a completed Phase 2 ovarian cancer study. It followed months of data presentations and an update on constrained cash levels. With an effective $100 million shelf already in place, investors may focus on how upcoming communications balance clinical progress with financing plans and dilution risk.

Key Terms

clinical trial, immune checkpoint inhibitor, metastatic pancreatic cancer, Phase 2 clinical trial

4 terms

clinical trial medical

"with an emphasis on the ongoing DURIPANC clinical trial in collaboration"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

immune checkpoint inhibitor medical

"AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab)"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

metastatic pancreatic cancer medical

"Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer."

A serious form of cancer that began in the pancreas and has spread to other parts of the body, such as the liver or lungs; think of it like a fire that started in one room and has moved through the house. It matters to investors because metastatic disease usually signals advanced illness with limited treatment options, influencing the commercial prospects of therapies, clinical trial success, healthcare costs, and the financial outlook for companies working on diagnostics or treatments.

Phase 2 clinical trial medical

"a completed Phase 2 clinical trial performed in collaboration with Merck"

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

AI-generated analysis. Not financial advice.

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ET

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. 

As part of the event, Equels will participate in a moderated “fireside” chat that will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer. Equels will also discuss the importance of a completed Phase 2 clinical trial performed in collaboration with Merck Sharp & Dohme LLC (“Merck”), which found that the combination therapy of Ampligen and Merck’s Keytruda (pembrolizumab) was well-tolerated and demonstrated clinical benefit in the treatment of advanced recurrent ovarian cancer. An abstract detailing the trial was recently presented at the 40^th Annual SITC Meeting.

Prior to the event, interested parties may submit questions in advance by emailing aim@jtcir.com. Equels will answer as many questions as possible in the time allowed.

A live video webcast of the fireside chat will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days. 

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

When will AIM (AIM) CEO Thomas Equels speak on the Virtual Investor Closing Bell Series?

He will speak on Thursday, December 4, 2025 at 4:00 PM ET.

What topics will AIM (AIM) cover in the fireside chat on December 4, 2025?

Discussion will focus on Ampligen clinical and regulatory strategy, the DURIPANC trial with Imfinzi, and a completed Phase 2 trial with Keytruda.

What is the DURIPANC trial AIM (AIM) will discuss on December 4, 2025?

DURIPANC is a trial combining Ampligen and AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer.

How can investors submit questions for AIM's (AIM) December 4, 2025 webcast?

Submit questions in advance by emailing aim@jtcir.com.

Will the AIM (AIM) fireside chat on December 4, 2025 be available to watch later?

Yes. A live webcast will stream on the company's Events page and a replay will be available two hours after the live presentation for 90 days.

What Phase 2 trial results will AIM (AIM) reference during the December 4, 2025 presentation?

They will reference a completed Phase 2 trial with Merck where Ampligen plus Keytruda was reported as well-tolerated and showed clinical benefit; an abstract was presented at the 40th Annual SITC Meeting.